Skip to main content

Table 4 Comparison of CAEBV with and without CAD

From: Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case–control study

  Case group (n = 10) Control group (n = 20) P Value
Course of disease (d) 70.57 86.31 0.693
Lymphadenopathy 5 13 0.625
Hepatomegaly 10 13 4.565
Splenomegaly 8 15 0.093
WBC (× 109/L) 5.03 (1.49–9.91) 4.82 (1.13–12.98) 0.205
ANC (× 109/L) 2.66 (0.42–5.11) 1.74 (0.36–7.89) 0.473
Hb (g/L) 106.00 (73.00–131.00) 105.00 (21.00–341.00) 1.000
PLT (× 109/L) 137.00 (30.00–422.00) 187.00 (21.00–341.00) 0.890
ALT (U/L) 230. 70 (22.80–1928.00) 109.85 (19.30–695.00) 0.090
AST (U/L) 124.80 (12.20–1806.00) 46.50 (9.90–662.90) 0.450
TG (mmol/L) 2.91 (1.20–5.24) 1.71 (0.66–5.71) 0.797
Fib (g/L) 2.12 (1.35–3.11) 1.29 (0.90–3.50) 0.890
CK-MB (U/L) 21.00 (10.00–33.00) 17.50 (6.00–45.00) 0.598
LDH (U/L) 433.500 (226.00–9934.00) 219.50 (201.00–1393.00) 0.009
CD4 + /CD8 +  0.75 (0.02–2.03) 2.31 (0.73–7.95) 0.049
SF (ug/L) 162.3 (27.80–91,893.20) 156.05 (24.70–17,043.00) 0.008
sCD25 (ng/L) 3848.40 (1504.00–23,684.00) 9282.20 (1500.00–40,623.00) 0.080
EBV (plasma) (Copies/mL) 1.81 (0.15–176.00) × 104 2.65 (0.15–755.00) × 104 0.284
EBV (whole blood) (Copies/mL) 1.18 (0.02–3.96) × 107 0.17 (0.016–3.97) × 107 0.992
NK cell activity (%) 15.30 (12.84–20.52) 14.52 (10.82–50.80) 0.282
IFN-γ (ng/L) 13.68 (3.41–790.41) 76.29 (0.00–769.91) 0.585
TNF-α (ng/L) 2.66 (0.00–525.62) 2.37 (0.00–244.33) 0.026
IL-6 (ng/L) 14.24 (4.98–2500.00) 31.64 (0.00–2500.00) 0.384
IL-10 (ng/L) 5.14 (1.79–270.01) 6.14 (1.93–75.72) 0.030
  1. WBC white blood cell, ANC neutrophil, Hb hemoglobin, PLT platelet, ALT: alanine transaminase, AST aspartate transaminase, TG triglyceride, Fib fibrinogen, CK-MB creatine kinase MB, LDH lactic dehydrogenase, SF serum ferritin, EBV Epstein–Barr virus, IFN-γ Interferon-γ, TNF-α tumor necrosis factor-α, IL interleukin